Key terms
About PXMD
PaxMedica, Inc. is a clinical stage biopharmaceutical company. It engages in the business of developing drug candidates for the treatment of autism spectrum disorder, Fragile X syndrome tremor-ataxia, and Human African Trypanosomiasis. The company was founded by Michael L. Derby on April 5, 2018 and is headquartered in Tarrytown, NY.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest PXMD news
Apr 16
4:34pm ET
PaxMedica announces request from MOH for emergency access to IV suramin
Apr 11
4:33pm ET
PaxMedica provides update on potential PAX-101 NDA submission
Mar 13
8:35am ET
PaxMedica releases lastest company presentation
Mar 13
8:22am ET
PaxMedica Releases Updated Investor Presentation Online
No recent press releases are available for PXMD
PXMD Financials
Key terms
Ad Feedback
PXMD Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
PXMD Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range